Detection method of 15N-p-Tau protein, p-Tau protein or fragment thereof, kit and application

By preparing 15N-p-Tau217 protein and immuno-enriched mass spectrometry detection method, the problem of accurate quantification of p-Tau217 protein detection in early diagnosis of Alzheimer's disease was solved, and high sensitivity and high accuracy detection was achieved, simplifying operation The process overcomes the problems of reproducibility and accuracy deviation in the prior art.

CN119019528AActive Publication Date: 2024-11-26NANJING MASS SPECTROMETRY MEDICAL TECH CO LTD +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411207819.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-26
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

The prior art is difficult to achieve accurate quantification of early diagnosis of Alzheimer's disease, especially due to the low abundance of p-Tau217 protein in peripheral blood and complex detection, resulting in poor reproducibility and deviation of accuracy inside and outside the laboratory.

Method used

By preparing 15N-p-Tau217 protein and combining immuno-enriching and mass spectrometry detection methods, accurate quantitative analysis is performed using the characteristics of isotope-labeled proteins, simplifying the sample pretreatment steps, including sample dilution, immune-enriching, cleaning, digestion and desalting treatment. , directly perform mass spectrometry detection.

Benefits of technology

Improve the precision and credibility of the detection, shorten the detection time, reduce the sample size requirement, simplify the operation process, overcome the problems of poor reproducibility and deviation in the prior art, and provide the Alzheimer High sensitivity and high accuracy methods for early diagnosis of Silence Disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019528A_ABST
    Figure CN119019528A_ABST
Patent Text Reader

Abstract

The invention discloses a detection method and kit for 15N-p-Tau 217 protein, p-Tau protein or fragments thereof and application, and relates to the technical field of protein spectrum detection. The stable isotope labeled 15N-p-Tau-217 protein is added during pretreatment, the method can be used for accurate quantification of the Tau-217 protein or the fragment thereof, the detection method is simple in step, short in detection time, high in sensitivity, good in precision and high in detection result credibility, mass spectrum detection pretreatment can be completed only through five steps, the required sample size is reduced, the detection time is shortened, and the detection cost is reduced. The method has important application value and significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of protein spectrum detection, and in particular to a 15 Detection method, kit and application of Np-Tau 217 protein, p-Tau protein or fragments thereof. Background Art

[0002] Alzheimer's Disease (AD) is a neurodegenerative disease with insidious onset and complex pathology. Its clinical features include irreversible brain damage, cognitive impairment, and decreased ability to take care of oneself in daily life, which can eventually develop into dementia and death. With the aging of the global population, the prevalence and socioeconomic burden of AD continue to increase, which has become one of the major challenges facing global public health. It has developed into the most common dementia and the main cause of increased disability among the elderly worldwide. At present, the clinical diagnosis of AD mainly relies on imaging technology combined with cognitive testing, and the disease is usually diagnosed in the middle and late stages. Although there is no effective treatment for AD, early diagnosis and intervention are still beneficial to reduce neurological damage, delay disease progression, and thus improve the quality of life of patients.

[0003] At present, the main diagnostic methods for AD are neuropsychological scales, imaging examinations, biomarker detection, etc. Neuropsychological scale assessments have large fluctuations in test results due to differences in the subjects' education level and personal understanding ability; neuroimaging tests mainly include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), etc., which are also strong evidence for AD diagnosis. CT can directly show brain atrophy in AD patients, but its value is limited due to poor soft tissue resolution. MRI and PET are expensive and not suitable for population screening.

[0004] The pathological characteristics of AD patients are mainly the extracellular deposition of amyloid β (Aβ) in the brain to form senile plaques, and the hyperphosphorylation of Tau protein causes neurofibrillary tangles in brain nerve cells. In the very early stage of AD, the levels of certain protein markers in cerebrospinal fluid (CSF), such as Aβ40, Aβ42, total Tau protein (T-Tau), and hyperphosphorylated Tau protein (p-Tau), will change. However, in order to detect markers in CSF clinically, CSF is often obtained through lumbar puncture. However, this method is an invasive operation, which is very harmful to patients, expensive, and has limited patient acceptance, which is not conducive to the early diagnosis of AD. Studies have found that the blood-brain barrier of AD patients is damaged, which causes certain protein markers in CSF to cross the blood-brain barrier in the early stage of the disease and enter the peripheral blood circulation, thereby causing blood protein marker levels to change significantly in the very early stage of the disease. Therefore, the non-invasive detection technology of AD protein markers in peripheral blood has become the most potential early screening and follow-up method due to its convenient sample collection and low trauma, bringing new hope for the early diagnosis of AD.

[0005] In the early stage of AD, only a small amount of protein markers can cross the blood-brain barrier from CSF into the peripheral circulation, and their abundance in the blood is extremely low (fM level). Since the target protein needs to be extracted from the blood matrix, a series of operations are involved, and the operation process will inevitably bring certain losses, resulting in poor reproducibility within and outside the laboratory, and large deviations from the actual content. Therefore, it is urgent to develop an absolute quantitative method with high precision and high accuracy to make the measured value as consistent as possible with the actual concentration of the target protein. Isotope-labeled proteins have the same amino acid sequence, immune enrichment effect, distribution behavior, liquid chromatography retention time, mass spectrometry ionization efficiency and secondary fragmentation ions as the target protein. Due to the different mass numbers, the ratio of the peak intensities of the two can be obtained on the mass spectrum. The amount of the corresponding hydrolyzed peptide in the sample is further calculated by the amount of the isotope-labeled peptide, and finally the amount of the corresponding protein is obtained according to the stoichiometric value of the peptide. However, the binding extraction, denaturation enzymatic hydrolysis and detection process that can simulate endogenous proteins has not been widely used in the absolute quantification of proteins because it is difficult to obtain. Furthermore, there are no reports on the preparation and application of p-Tau217 isotope-labeled protein. Summary of the invention

[0006] In view of this, the main purpose of the present invention is to provide a 15 The present invention provides a detection method, a kit and an application of Np-Tau 217 protein, p-Tau protein or a fragment thereof, in order to at least partially solve the above technical problems.

[0007] In order to achieve the above object, as a first aspect of the present invention, there is provided a 15 Np-Tau protein, 15Np-Tau protein was prepared by the following method:

[0008] 1) Add GSK3β diluted with kinase dilution buffer I to a pre-cooled centrifuge tube, then add 15 N-Tau;

[0009] 2) Add ATP diluted in kinase assay buffer, mix thoroughly and incubate;

[0010] 3) Add GSK3β inhibitor, terminate the reaction, purify and obtain the 15 Np-Tau protein.

[0011] Preferably, the GSK3β diluted in the kinase dilution buffer I in step 1) is specifically:

[0012] Dilute GSK3β to 0.1 μg / μl with Kinase Dilution Buffer I and add 5 μL-50 μL.

[0013] Preferably, in step 1), the diluted kinase assay buffer 15 N-Tau is specifically:

[0014] Kinase Assay Buffer 15 N-Tau was diluted to 1 mg / mL and the amount added was 5 μL-50 μL.

[0015] Preferably, the ATP diluted with the kinase detection buffer in step 2) is specifically:

[0016] Dilute the 0.1M ATP stock solution to 250μM with kinase assay buffer and add 2.5μL-12.5μL.

[0017] Preferably, the step 3) of adding the GSK3β inhibitor comprises: adding an aqueous solution of the GSK3β inhibitor with a concentration of 100 ug / mL and an amount of 0.75 μL-7.5 μL.

[0018] In a second aspect, the present invention provides a method for detecting Tau protein or a fragment thereof, the method comprising adding the method described in the first aspect during sample pretreatment. 15 Steps of Np-Tau protein.

[0019] Preferably, the method comprises at least the following steps:

[0020] 1) Sample pretreatment: Add sample diluent to the sample, then add the 15 Np-Tau protein, to obtain solution A;

[0021] 2) Immunoenrichment: Add the nanomagnetic microsphere-p-Tau 217 antibody complex to solution A for incubation, and pass through a magnetic rack to obtain a purified immune-enriched complex (i.e., target protein-Tau 217 antibody-nanomagnetic microsphere complex);

[0022] 3) washing: washing the immunoenriched complex with a nonionic surfactant (such as NP40) to obtain a washed complex;

[0023] 4) adding NH4HCO3 to dissolve the washed complex, and then digesting and terminating;

[0024] 5) Desalting, vacuum concentration and mass spectrometry injection;

[0025] 6) Perform detection using mass spectrometry and output the results.

[0026] Preferably, the sample is a CSF, blood or plasma sample;

[0027] Preferably, the sample diluent in step 1) comprises: Tris-HCl, NaCl, EDTA (ethylenediaminetetraethylene glycol acid), protease inhibitors and phosphatase inhibitors; and / or

[0028] In step 1), the sample diluent further includes NP40 and / or Tween 20 (polyether sulfate nonionic surfactant).

[0029] Preferably, the sample diluent in step 1) comprises: 20-80 mM Tris-HCl, 30-80 mM NaCl, 1-10 mM EDTA (ethylenediaminetetraethylene glycol acid), and 0.02%-0.2% protease inhibitor and 0.02%-0.2% phosphatase inhibitor by mass fraction; wherein the concentration of Tris-HCl can be 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM or all values ​​within the range, because Due to space limitations, they are not listed one by one; the concentration of NaCl can be 30mM, 35mM, 40mM, 45mM, 50mM, 55mM, 60mM, 65mM, 70mM, 75mM or all values ​​within the range, which are not listed one by one due to space limitations; the concentration of EDTA can be 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM or all values ​​within the range, which are not listed one by one due to space limitations. The role of sample diluent: reduce the viscosity of plasma, make the antibody microspheres evenly distributed in the plasma, and increase the capture probability of the target protein; create a buffer system and the presence of non-ionic surfactants, which are conducive to the binding of antigens and antibodies and reduce the nonspecific adsorption of microspheres to non-target proteins; since blood contains a series of biologically active enzymes, it can enzymatically hydrolyze proteins in vitro, and the addition of protease inhibitors and phosphatase inhibitors can inhibit the enzymatic hydrolysis of target proteins by biologically active enzymes.

[0030] And / or the sample diluent in step 1) further includes NP40 and / or Tween 20 with a mass fraction of 0.1%-1%, and the mass fraction of NP40 and / or Tween 20 can be 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1% or all values ​​within the range, which are not listed one by one due to space limitations. And / or

[0031] Step 1) p-Tau- 15 N-peptide segment is 0.5-5pg / mL 15 Np-Tau217 aqueous solution, p-Tau- 15 The concentration of the N-peptide segment can be 0.5pg / mL, 1pg / mL, 1.5pg / mL, 2pg / mL, 2.5pg / mL, 3pg / mL, 3.5pg / mL, 4pg / mL, 4.5pg / mL, 5pg / mL or all values ​​within the said range, which are not listed one by one due to space limitations.

[0032] Preferably, step 2) comprises: adding the nanomagnetic microsphere-p-Tau 217 antibody complex to solution A, incubating with rotation at room temperature for at least 2 hours, and passing through a magnetic rack to obtain a purified immune-enriched complex (i.e., target protein-p-Tau 217 antibody-nanomagnetic microsphere complex);

[0033] The nanomagnetic microsphere-p-Tau 217 antibody complex has a monoclonal antibody for recognizing the p-Tau 217 site, and its purpose is to capture the target protein (p-Tau 217) in plasma to obtain an immune-enriched complex (i.e., the target protein-p-Tau 217 antibody-nanomagnetic microsphere complex). Nanomagnetic microspheres superparamagnetic microspheres are easy to demagnetize, which is helpful for subsequent separation and efficient washing. Even after multiple magnetizations, the performance of superparamagnetic nanomicrospheres remains unchanged, and the repeatability is good. Since the magnetic frame has a built-in magnet, the magnetic nanomagnetic microsphere-p-Tau 217 antibody complex can be fixed on the container wall to achieve solid-liquid separation, which is conducive to automated conversion. By combining it with a specific antibody, the solution and the nanomagnetic microsphere-p-Tau 217 antibody complex can be separated without centrifugation, simplifying the extraction process.

[0034] Preferably, step 3) comprises: washing the immuno-enriched complex at least three times with a PBS solution containing 0.1% to 0.5% NP40 by mass.

[0035] The role of the nonionic surfactant (NP40 in PBS) is to remove nonspecific adsorption on the surface of the nanomagnetic microsphere-antibody complex. The mass fraction of NP40 in the PBS solution can be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45% or all values ​​within the range, which are not listed one by one due to space limitations.

[0036] Preferably, step 4) comprises: adding 20-200mM NH4HCO3 to dissolve the washed complex, adding trypsin to digest for at least 8h, and adding 10% formic acid aqueous solution to terminate; the main function of ammonium bicarbonate (NH4HCO3) is to provide an alkaline hydrolysis environment to ensure the highest activity of trypsin (optimal pH 8-9), and decompose p-Tau217 protein into specific peptides that can be used for mass spectrometry detection. The concentration of NH4HCO3 can be 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 110mM, 120mM, 130mM, 140mM, 150mM, 160mM, 170mM, 180mM, 190mM or all values ​​within the range, which are not listed one by one due to space limitations.

[0037] Preferably, the desalination in step 5) comprises:

[0038] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0039] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0040] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0041] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0042] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0043] In the above steps, salt ions will remain, which will not only interfere with mass spectrometry analysis, but also may damage the chromatographic column. Since the stationary phase on the C18 column is composed of silica gel particles modified by octyl (C18) silane compounds with a carbon chain length of 18 carbon atoms, its strong hydrophobicity can effectively retain peptides and remove salt ions in the desalting step.

[0044] Preferably, the vacuum concentration and mass spectrometry sampling in step 5) comprises: passing the desalted sample through a vacuum concentration centrifuge and drying; the mass spectrometer is an orbital ion trap mass spectrometer;

[0045] Preferably, the orbital ion trap mass spectrometry sampling in step 5) comprises: re-dissolving the dried sample with an aqueous solution of 0.1% by volume formic acid, and injecting the sample after oscillation and centrifugation;

[0046] Preferably, the reconstituted sample is added prior to mass spectrometry injection. 15 The Np-Tau 217 stock solution was vortexed for 1 min, centrifuged for 30 s, and placed in the mass spectrometer.

[0047] Preferably, the method comprises at least the following steps:

[0048] 1) Sample pretreatment: adding a sample diluent to the sample to obtain solution A; the sample diluent comprises: 0.1%-1% NP40 by mass, 0.1%-1% Tween 20 by mass, 20-80mM Tris-HCl, 30-80mM NaCl, 0.02%-0.2% protease inhibitor by mass, and 0.02%-0.2% phosphatase inhibitor by mass; the sample is a CSF, blood or plasma sample; wherein p-Tau- 15N-peptide fragment is 0.5-5pg / mL 15 Np-Tau217 aqueous solution;

[0049] 2) Immunoenrichment: Add the nanomagnetic microsphere-antibody complex to solution A, incubate with rotation at room temperature for at least 2 hours, and pass through a magnetic rack to obtain a purified immune-enriched complex;

[0050] 3) Washing: Wash the immuno-enriched complexes at least three times with a PBS solution containing 0.1% to 0.5% NP40 by mass to obtain washed complexes;

[0051] 4) Digestion: The washed complex was re-dissolved in 20-200 mM NH4HCO3, and then digested with trypsin for at least 8 h, and terminated by adding 10% by mass formic acid aqueous solution;

[0052] 5) Desalination:

[0053] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0054] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0055] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0056] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0057] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0058] 6) Dry the desalted sample using a vacuum concentrator centrifuge, re-dissolve the dried sample in 0.1% formic acid water, shake and centrifuge, and then inject;

[0059] 7) Perform detection using mass spectrometry and output the results.

[0060] The principle of the present invention is as follows: the present invention specifically adsorbs the target protein (p-Tau217) in the sample onto the immune microspheres (nanomagnetic p-Tau 217 antibody) by means of immune enrichment; the nanomagnetic microspheres have superparamagnetism, so the immune-enriched complex is placed on a magnetic rack with a magnetic field, the immune microsphere complex adsorbed with the target protein can be adsorbed, and other impurities that cannot be adsorbed by the immune microspheres cannot remain in the magnetic field, so they can be washed and removed; after thorough washing, the adsorbed antigen-antibody complex is digested with trypsin to separate it, the antibody is combined with the nanomagnetic microspheres, and the target protein is released; then, after termination, desalting, drying, centrifugation and other steps, the target protein is completely separated. The isotope-labeled protein has the same amino acid sequence, immune enrichment effect, distribution behavior, liquid chromatography retention time, mass spectrometry ionization efficiency and secondary fragmentation ions as the target protein. Due to the different mass numbers, the ratio of the peak intensities of the two can be obtained on the mass spectrum. The amount of the corresponding hydrolyzed peptide in the sample can be further calculated based on the amount of the isotope-labeled peptide. Finally, the amount of the corresponding protein can be obtained based on the stoichiometric value of the peptide, and can be used to diagnose and / or treat subjects suffering from or at risk of neurological or neurodegenerative diseases.

[0061] It should be noted that the raw data output by the orbital ion trap mass spectrometer needs to be imported into the skyline software for secondary processing before the mass spectrometry signal data can be converted into content results.

[0062] In a third aspect, the present invention provides a detection kit for p-Tau 217 protein or a fragment thereof, the kit comprising:

[0063] 1) Pretreatment module: at least including sample diluent and the 15 Np-Tau217 protein, wherein the sample diluent comprises: 0.1%-1% by mass of NP40 and / or Tween 20, 20-80 mM Tris-HCl, 30-80 mM NaCl, 0.02%-0.2% by mass of protease inhibitors, and 0.02%-0.2% by mass of phosphatase inhibitors;

[0064] 15 Np-Tau protein is 0.5-5pg / mL 15 Np-Tau 217 aqueous solution.

[0065] 2) Immunoenrichment module: at least including nanomagnetic microsphere-p-Tau 217 antibody complex;

[0066] 3) Cleaning the digestion module: at least a PBS solution containing 0.1% to 0.5% NP40 by mass and a 20-200 mM NH4HCO3 solution;

[0067] 4) Desalination module: at least including methanol, 80% by volume acetonitrile aqueous solution, and 1% by volume formic acid aqueous solution;

[0068] 5) Drying and sampling module: at least including a 1% by volume formic acid aqueous solution.

[0069] In a fourth aspect, the present invention provides use of a kit for the p-Tau 217 protein or a fragment thereof as described in the third aspect in the early diagnosis of Alzheimer's disease.

[0070] Based on the above technical solution, it can be seen that the p-Tau 217- 15 Compared with the prior art, the detection method, kit and application of N-peptide, p-Tau protein or its fragments have at least one of the following beneficial effects:

[0071] The present invention adds stable isotope labeled 15 Np-Tau217 protein can be used for accurate quantification of p-Tau 217 protein or its fragments. Since the isotope-labeled protein has the same amino acid sequence, immune enrichment effect, distribution behavior, liquid chromatography retention time, mass spectrometry ionization efficiency and secondary fragmentation ions as the target protein, and due to the different mass numbers, the ratio of the peak intensities of the two can be obtained on the mass spectrum, and the amount of the corresponding hydrolyzed peptide in the sample can be further calculated by the amount of isotope-labeled peptide, and finally the amount of the corresponding protein can be obtained according to the stoichiometric value of the peptide. In particular, it is added during pretreatment, and the monitoring of the entire process (including sample dilution, immune enrichment, washing, digestion, desalting and other steps) can effectively overcome the losses caused by the need to extract p-Tau 217 from the blood matrix, as well as the poor reproducibility inside and outside the laboratory and the large deviation from the actual content.

[0072] In addition, the detection method of phosphorylated Tau-217 protein or its fragments of the present invention has simple steps, short detection time, high sensitivity, good precision, high credibility of detection results, and only 5 steps are needed to complete the mass spectrometry detection pre-treatment, and the required sample volume is reduced by about 75%, wherein the cleaning step is simplified, the acid precipitation, acid cleaning and solid phase extraction steps in the prior art are omitted, and the digestion and incubation time is greatly shortened. The present invention solves the problems of the existing Alzheimer's disease detection kit, such as complex operation, long time consumption, low sensitivity, poor precision, lack of accurate prediction ability of Alzheimer's disease, and has important application value and significance. BRIEF DESCRIPTION OF THE DRAWINGS

[0073] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments.

[0074] Figure 1 is the p-Tau 217IP-MS flow chart;

[0075] Figure 2 is a graph showing the difference in p-Tau 217 concentration between the AD patient group and the healthy population (control group) in Example 4;

[0076] Figure 3 This is the p-Tau 217 protein calibration curve of Comparative Example 3. DETAILED DESCRIPTION

[0077] The prior art mass spectrometry detection of markers of Alzheimer's disease has complicated pre-processing steps, complex operating procedures, long time consumption and low sensitivity. After careful research, the inventors of the present invention have simplified and optimized the above steps, so that a higher detection accuracy and detection limit can be achieved through simpler operations. Specifically, as a first aspect of the present invention, there is provided a 15 Np-Tau protein, 15 Np-Tau protein was prepared by the following method:

[0078] 1) Add GSK3β diluted with kinase dilution buffer I to a pre-cooled centrifuge tube, then add 15 N-Tau;

[0079] 2) Add ATP diluted in kinase assay buffer, mix thoroughly and incubate;

[0080] 3) Add GSK3β inhibitor, terminate the reaction, purify and obtain the 15 Np-Tau protein.

[0081] As a preferred embodiment, the GSK3β diluted in the kinase dilution buffer I in step 1) is specifically:

[0082] Dilute GSK3β to 0.1 μg / μl with Kinase Dilution Buffer I (Kinase Dilution Buffer I) and add 5-50 μl.

[0083] In a preferred embodiment, the step 1) diluting the kinase assay buffer 15 N-Tau is specifically:

[0084] Kinase Assay Buffer 15 N-Tau was diluted to 1 mg / mL and the amount added was 5 μL-50 μL.

[0085] In a preferred embodiment, the ATP diluted with the kinase detection buffer in step 2) is specifically:

[0086] Dilute the 0.1M ATP stock solution to 250μM with kinase assay buffer and add 2.5μL-12.5μL.

[0087] In a preferred embodiment, the step 3) of adding the GSK3β inhibitor specifically comprises: adding an aqueous solution of the GSK3β inhibitor with a concentration of 100 ug / mL and an addition amount of 0.75 μL-7.5 μL.

[0088] In a second aspect, the present invention provides a method for detecting Tau protein or a fragment thereof, the method comprising adding the method described in the first aspect during sample pretreatment. 15 Steps of Np-Tau protein.

[0089] In a preferred embodiment, the method comprises at least the following steps:

[0090] 1) Sample pretreatment: Add sample diluent to the sample, then add the 15 Np-Tau protein, to obtain solution A;

[0091] 2) Immunoenrichment: Add the nanomagnetic microsphere-p-Tau 217 antibody complex to solution A for incubation, and pass through a magnetic rack to obtain a purified immune-enriched complex (i.e., target protein-Tau 217 antibody-nanomagnetic microsphere complex);

[0092] 3) washing: washing the immunoenriched complex with a nonionic surfactant (such as NP40) to obtain a washed complex;

[0093] 4) adding NH4HCO3 to dissolve the washed complex, and then digesting and terminating;

[0094] 5) Desalting, vacuum concentration and mass spectrometry injection;

[0095] 6) Perform detection using mass spectrometry and output the results.

[0096] In a preferred embodiment, the sample is a CSF, blood or plasma sample;

[0097] In a preferred embodiment, the sample diluent in step 1) comprises: Tris-HCl, NaCl, EDTA (ethylenediaminetetraethylene glycol acid), protease inhibitors and phosphatase inhibitors; and / or

[0098] In step 1), the sample diluent further includes NP40 and / or Tween 20 (polyether sulfate nonionic surfactant).

[0099] In a preferred embodiment, the sample diluent in step 1) comprises: 20-80 mM Tris-HCl, 30-80 mM NaCl, 1-10 mM EDTA (ethylenediaminetetraethylene glycol acid), and 0.02%-0.2% by mass of protease inhibitors and 0.02%-0.2% by mass of phosphatase inhibitors; and / or

[0100] The sample diluent in step 1) further comprises NP40 and / or Tween 20 at a mass fraction of 0.1%-1%; and / or

[0101] Preferably, in step 1) 15 Np-Tau protein is 0.5-5pg / mL 15 Np-Tau217 aqueous solution.

[0102] In a preferred embodiment, step 2) comprises: adding the nanomagnetic-p-Tau 217 antibody microsphere complex to solution A, incubating with rotation at room temperature for at least 2 hours, passing through a magnetic rack to obtain a purified immune-enriched complex (i.e., target protein-Tau 217 antibody-nanomagnetic microsphere complex);

[0103] The nanomagnetic microsphere-p-Tau 217 antibody complex has a monoclonal antibody for recognizing the p-Tau 217 site, and its purpose is to capture the target protein (p-Tau 217) in plasma to obtain an immune-enriched complex (i.e., the target protein-p-Tau 217 antibody-nanomagnetic microsphere complex). Nanomagnetic microspheres superparamagnetic microspheres are easy to demagnetize, which is helpful for subsequent separation and efficient washing. Even after multiple magnetizations, the performance of superparamagnetic nanomicrospheres remains unchanged, and the repeatability is good. Since the magnetic frame has a built-in magnet, the nanomagnetic microsphere-p-Tau 217 antibody complex can be fixed on the container wall to achieve solid-liquid separation, which is conducive to automated conversion. By combining it with a specific antibody, the solution and the nanomagnetic microsphere-p-Tau 217 antibody complex can be separated without centrifugation, simplifying the extraction process.

[0104] In a preferred embodiment, step 3) comprises: washing the immuno-enriched complex at least three times with a PBS solution containing 0.1% to 0.5% NP40 by mass.

[0105] In a preferred embodiment, step 4) includes: adding 20-200 mM NH4HCO3 to dissolve the washed complex, adding trypsin to digest for at least 8 hours, and adding 10% by volume aqueous formic acid to terminate the process; the main function of ammonium bicarbonate (NH4HCO3) is to provide an alkaline hydrolysis environment to ensure the highest activity of trypsin (optimal pH 8-9), and to decompose the p-Tau217 protein into specific peptides that can be used for mass spectrometry detection.

[0106] In a preferred embodiment, the desalination in step 5) comprises:

[0107] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0108] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0109] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0110] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0111] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0112] In the above steps, salt ions will remain, which will not only interfere with mass spectrometry analysis, but also may damage the chromatographic column. Since the stationary phase on the C18 column is composed of silica gel particles modified by octyl (C18) silane compounds with a carbon chain length of 18 carbon atoms, its strong hydrophobicity can effectively retain peptides and remove salt ions in the desalting step.

[0113] In a preferred embodiment, the vacuum concentration and mass spectrometry sampling in step 5) comprises: passing the desalted sample through a vacuum concentration centrifuge and drying; the mass spectrometer is an orbital ion trap mass spectrometer;

[0114] In a preferred embodiment, the orbital ion trap mass spectrometer injection in step 5) comprises: re-dissolving the dried sample with an aqueous solution of 0.1% formic acid by volume, and injecting the sample after oscillation and centrifugation;

[0115] In a preferred embodiment, the reconstituted sample is added prior to mass spectrometry injection. 15 The Np-Tau 217 stock solution was vortexed for 1 min, centrifuged for 30 s, and placed in the mass spectrometer.

[0116] In a preferred embodiment, the method comprises at least the following steps:

[0117] 1) Sample pretreatment: adding a sample diluent to the sample to obtain solution A; the sample diluent comprises: 0.1%-1% NP40 by mass, 0.1%-1% Tween 20 by mass, 20-80mM Tris-HCl, 30-80mM NaCl, 0.02%-0.2% protease inhibitor by mass, and 0.02%-0.2% phosphatase inhibitor by mass; the sample is a CSF, blood or plasma sample; wherein, 15 Np-Tau protein is 0.5-5pg / mL 15 Np-Tau217 aqueous solution;

[0118] 2) Immunoenrichment: Add the nanomagnetic microsphere-antibody complex to solution A, incubate with rotation at room temperature for at least 2 hours, and pass through a magnetic rack to obtain a purified immune-enriched complex;

[0119] 3) Washing: Wash the immuno-enriched complexes at least three times with a PBS solution containing 0.1-0.5% NP40 by mass to obtain washed complexes;

[0120] 4) Digestion: The washed complex is re-dissolved in 20-200 mM NH4HCO3, and then digested with trypsin for at least 8 h, and terminated by adding 10% by mass formic acid aqueous solution;

[0121] 5) Desalination:

[0122] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0123] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0124] ③ Add 200 μL of 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0125] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0126] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0127] 6) Dry the desalted sample using a vacuum concentrator centrifuge, re-dissolve the dried sample in 0.1% formic acid water, shake and centrifuge, and then inject;

[0128] 7) Perform detection using mass spectrometry and output the results.

[0129] The principle of the present invention is as follows: the present invention specifically adsorbs the target protein (p-Tau217) in the sample on the immune microspheres (nanomagnetic microspheres-Tau 217 antibodies) by means of immune enrichment; the nanomagnetic microspheres have superparamagnetism, so the immune-enriched complex is placed on a magnetic rack with a magnetic field, the immune microsphere complex adsorbed with the target protein can be adsorbed, and other impurities that cannot be adsorbed by the immune microspheres cannot remain in the magnetic field, so they can be washed and removed; after thorough washing, the adsorbed antigen-antibody complex is digested with trypsin to separate it, the antibody is combined with the nanomagnetic microspheres, and the target protein is released; then, after termination, desalting, drying, centrifugation and other steps, the target protein is completely separated. The isotope-labeled protein has the same amino acid sequence, immune enrichment effect, distribution behavior, liquid chromatography retention time, mass spectrometry ionization efficiency and secondary fragmentation ions as the target protein. Due to the different mass numbers, the ratio of the peak intensities of the two can be obtained on the mass spectrum. The amount of the corresponding hydrolyzed peptide in the sample can be further calculated based on the amount of the isotope-labeled peptide. Finally, the amount of the corresponding protein can be obtained based on the stoichiometric value of the peptide, and can be used to diagnose and / or treat subjects suffering from or at risk of neurological or neurodegenerative diseases.

[0130] In a third aspect, the present invention provides a detection kit for p-Tau 217 protein or a fragment thereof, the kit comprising:

[0131] 2) Pretreatment module: at least including sample diluent and the 15 Np-Tau217 protein, wherein the sample diluent comprises: 0.1%-1% by mass of NP40 and / or Tween 20, 20-80 mM Tris-HCl, 30-80 mM NaCl, 0.02%-0.2% by mass of protease inhibitors, and 0.02%-0.2% by mass of phosphatase inhibitors;

[0132] p-Tau- 15 N-peptide fragment is 0.5-5pg / mL 15 Np-Tau 217 aqueous solution.

[0133] 2) Immunoenrichment module: at least including nanomagnetic microsphere-p-Tau 217 antibody complex;

[0134] 3) Cleaning the digestion module: at least a PBS solution containing 0.1% to 0.5% NP40 by mass and a 20-200 mM NH4HCO3 solution;

[0135] 4) Desalination module: at least including methanol, 80% by volume acetonitrile aqueous solution, and 1% by volume formic acid aqueous solution;

[0136] 5) Drying and sampling module: at least including a 1% by volume formic acid aqueous solution.

[0137] In a fourth aspect, the present invention provides use of a kit for the p-Tau 217 protein or a fragment thereof as described in the third aspect in the early diagnosis of Alzheimer's disease.

[0138] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.

[0139] The conventional reagents and equipment used in the present invention, unless otherwise specified, are commercially available.

[0140] Collection of plasma samples: Peripheral blood from Alzheimer's disease patients and healthy subjects was collected from the blood bank of a municipal hospital in Anhui Province. After plasma was extracted from each peripheral blood sample, it was stored at -80℃ for future use.

[0141] Example 1 Preparation of immune microspheres (nanomagnetic microspheres-Tau 217 antibody)

[0142] Take two 10 μL portions of nanomagnetic microsphere suspension (10 mg / mL 0.1% BSA + 0.02% NaN3) and place them in a 1.5 mL EP tube. Wash them three times with 2 mM EDTA in PBS solution, 3 min / time, 1 mL / time. After removing the supernatant, add 4 μL of 100 μg / mL p-Tau217 antibody to the experimental group, and do not add p-Tau 217 antibody to the blank background group. Further add 500 μL PBS solution and rotate and incubate at 4 ° C for 8 h to obtain immune microspheres (nanomagnetic microsphere-p-Tau 217 antibody complex). Use the BCA method to deduct the blank background group as the zero point, test the protein in the solution before and after coupling, evaluate the antibody coupling efficiency, repeat 3 times, and the evaluation results of the experimental group are shown in Table 1. There is no result in the blank group, which is automatically deducted as the background. It can be seen from the data in Table 1 that the coupling efficiency of p-Tau 217 antibody and nanomagnetic microspheres is above 75%, and the coupling effect is good.

[0143] Table 1 Evaluation of antibody coupling efficiency

[0144] Serial number Uncoupled absorbance Absorbance after coupling Coupling efficiency 1 0.112 0.025 77.68% 2 0.111 0.027 75.68% 3 0.107 0.025 76.63%

[0145] Example 2 15 Preparation of Np-Tau 217 protein

[0146] 1) Reagent preparation

[0147] Reagent 1: Dilute GSK3β to 0.1 μg / μl (10 μg + 100 μL) with Kinase Dilution Buffer I (Kinase Dilution Buffer I);

[0148] Reagent 2: Use kinase assay buffer to 15 N-Tau was diluted to 1 mg / mL (50 μg 15 N-Tau + 50 μL kinase assay buffer);

[0149] Reagent 3: Dilute the 0.1M ATP stock solution to 250μM with kinase assay buffer (1mL water + 2.5μL 0.1M ATP);

[0150] Reagent 4: 100 μg / mL SB415286 aqueous solution.

[0151] 2) Phosphorylation reaction: Add 10 μL of reagent 1 to a pre-cooled microcentrifuge tube, then add 10 μL of reagent 2 to make the initial reaction volume reach 20 μL, vortex mix for 1 min, centrifuge for 30 s, add 5 μL of reagent 3, mix and incubate at 30°C for 30 min;

[0152] 3) Reaction termination: Add 1.5 μL 100ug / mL SB415286 to terminate the reaction, vortex mix for 2 minutes, and centrifuge for 30 seconds.

[0153] 4) Concentration determination: Take 1 μL of the solution after the reaction, add 379 μL of 100mM NH4HCO3 to dilute, vortex mix for 30 seconds, prepare a 1 μg / mL solution, take 100 μL of the solution and place it in a low-adsorption EP tube, add 1 μL 20 μg / mL trypsin and oscillate for 30 seconds, ultrasonicate for 30 seconds, place it on a constant temperature oscillator, digest at 37°C 1000rpm for 8 hours, then add 10% formic acid solution and vortex oscillate for 5 minutes to terminate the digestion, desalt, perform mass spectrometry detection, and use DDA (data-dependent acquisition) acquisition mode to obtain the mass spectrometry signal intensity of each phosphorylated protein. The results show that 15 The phosphorylation efficiency of N-Tau was 72.73%, of which the phosphorylation efficiency of threonine (T) was 54.55%. 15 The concentration of Np-Tau 217 was 20 μg / mL.

[0154] Example 3 p-Tau 217 mass spectrometry detection

[0155] (1) Reagent preparation:

[0156] 1) Preparation of sample diluent: 0.2 mL NP40, 2 mL 1 mM Tris-HCl, 0.14 g NaCl, 58.5 mg EDTA, 40 μL protease inhibitor, 40 μL phosphatase inhibitor and 37.8 mL water were mixed to prepare sample diluent;

[0157] 2) 15 Preparation of Np-Tau217 working solution: dilute with purified water 15 Np-Tau 217 stock solution was prepared to 1 μg / mL;

[0158] 3) Preparation of cleaning solution: Mix 0.05 mL NP40 with 100 mL PBS to obtain a 0.5% NP40 PBS solution;

[0159] 4) Preparation of digestion solution: Mix 197.64 mg of NH4CHO3 with 50 mL of purified water to obtain a concentration of 50 mM NH4CHO3;

[0160] 5) Preparation of trypsin solution: Mix 20 μg of trypsin with 1 mL of digestion solution;

[0161] 6) Preparation of reconstitution solution: Mix 10 μL of formic acid with 1 mL of purified water to prepare a 0.1% (v / v) formic acid water reconstitution solution.

[0162] (2) Basic processing steps:

[0163] 1) Sample pretreatment: Add sample diluent to 0.25-1 mL of sample, then add 10 μL 15 Np-Tau 217, vortex to mix, and obtain solution A;

[0164] 2) Immunoenrichment: The nanomagnetic microsphere-antibody complex was added to solution A successively, and incubated at room temperature for 2 hours with rotation to obtain an immunoenriched complex, i.e., a protein-antibody-microsphere complex;

[0165] 3) Washing: The protein-antibody-microsphere complex in 2) was placed on a magnetic stand for 1 min. After solid-liquid separation, the supernatant was removed, and 0.5% NP40 in PBS was added. The mixture was washed by rotation at 1 ml / time and 5 min / time. The operation was repeated 3 times to obtain a washed complex.

[0166] 4) Digestion: Add 1 mL of 50 mM NH4HCO3 solution to the complex after washing in 3), and perform rotation washing for 5 min / time. Repeat the operation 3 times, replace the solvent, add 1 μL of 20 μg / ml pancreatic enzyme, oscillate for 30 s, ultrasonicate for 30 s, place on a constant temperature oscillator, and digest at 37°C and 1000 rpm for 8 h. Then add 10% formic acid solution and vortex oscillate for 5 min to terminate the digestion;

[0167] 5) Desalination:

[0168] ① Add 200 μL methanol to the C18 centrifugal column and centrifuge at 2500 rpm for 5 min, then discard the filtrate;

[0169] ② Add 200 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0170] ③ Add 200 μL 1% formic acid aqueous solution and centrifuge at 2500 rpm for 5 min, and discard the filtrate;

[0171] ④ Add the acidified sample to the C18 centrifugal column and centrifuge at 1800 rpm for 10 min, then discard the filtrate;

[0172] ⑤ Add 80 μL of 80% acetonitrile aqueous solution and centrifuge at 2500 rpm for 5 min, and collect the filtrate;

[0173] 6) Place in a vacuum freeze dryer and spin centrifuge for 30 minutes to remove the solvent.

[0174] 7) Before mass spectrometry injection, add 10 μL of the reconstitution solution, shake and mix for 5 minutes, and separate for 30 seconds to prepare for mass spectrometry detection; then perform mass spectrometry detection. The mass spectrometry parameters are set as follows: Isolation window: 0.7; HCD: 30%; Orbitrap Resolution: 45000; scan range: 120-1500; RF lens: 50%; AGC: 100%; Maximun injection Time: 110. Chromatographic analysis time: 30 minutes. Injection volume: 5 μL; Chromatographic parameters are shown in Table 2.

[0175] Table 2 Chromatographic parameters

[0176] Time (min) Flow rate (μL / min) %B Curve Type 0 0.5 4.0 5 1.8 0.5 4.5 5 2.0 0.3 5.0 5 11 0.3 20.0 5 27 0.3 35.0 5 27.5 0.5 55.0 5 28 0.5 99.0 5 30 0.5 99.0 5

[0177] 8) Result calculation: The peak area of ​​the target peptide is compared with the peak area of ​​the isotope peptide, and then multiplied by the concentration of the isotope peptide to obtain the concentration of the target peptide, and then the concentration of the target peptide is converted into the concentration of the target protein.

[0178] (3) Sample dilution multiple screening: The plasma sample and the sample dilution were mixed in a ratio of 1:1, 1:2, 1:3, and 1:4. The other steps were the same as step (2). The peak area ratio of the target protein to the isotope-labeled protein and the ratio of the peak height of the target protein to the baseline at 1 min after the peak (S / N) were read using an orbital ion trap mass spectrometer to determine the optimal dilution ratio of the two. The results are shown in Table 3. As can be seen from the data in the table, the ratio of sample to dilution was p-Tau 217 / 15 NP-Tau217 was the highest and its signal-to-noise ratio was high, so the ratio of sample to diluent was determined to be 1:2.

[0179] Table 3 Determination results of the ratio of different samples to diluents

[0180]

[0181] (4) Sample diluent ratio: The sample diluent formula was designed as follows: 1) 0.5% NP40 + 60mM NaCl + 5mM EDTA + 0.1% protease inhibitor + 0.1% phosphatase inhibitor, the concentration of Tris-HCl was 20mM, 40mM, 60mM, 80mM, 2) 0.5% NP40 + 50mMTris-HCl + 5mM EDTA + 0.1% protease inhibitor + 0.1% phosphatase inhibitor, the concentration of NaCl was 30mM, 50mM, 70mM, 80mM, 3) 0.5% NP40 + 50mM Tris-HCl+60mMNaCl+0.1% protease inhibitor+0.1% phosphatase inhibitor, EDTA concentration is 2mM, 4mM, 6mM, 8mM, and the others are consistent with step 2). The peak area ratio of the target protein and the isotope-labeled protein, and the peak height of the target protein and the baseline ratio (S / N) at 1 min after the peak are read by an orbital ion trap mass spectrometer to determine the best dilution ratio of the two. The results are shown in Table 4. From the data in the table, it can be seen that the concentration of Tris-HCl in the sample diluent is within 20mM-80mM, the concentration of NaCl is within 30mM-80mM, and the concentration of EDTA is within 2mM-8mM. The detection concentration is basically stable, and the signal-to-noise ratio is greater than 10, which meets the quantitative requirements.

[0182] Table 4 Comparison results of different concentrations of Tris-HCl, NaCl and EDTA

[0183]

[0184] (5) Cleaning solution formula: The cleaning solution was prepared into the following four formulas, namely 0.5% NP40PBS, 0.1% NP40PBS, PBS and 0.1N NaCl. The other formulas were the same as step 2). The peak area ratio of the target protein to the isotope-labeled protein and the ratio of the peak height of the target protein to the baseline at 1 min after the peak (S / N) were read by an orbital ion trap mass spectrometer to determine the two optimal dilution ratios. The results are shown in Table 5. From the data in the table, it can be seen that the cleaning solution formulas are basically consistent with the theoretical concentrations when they are 0.5% NP40 PBS and 0.1% NP40 PBS, while the deviation from the theoretical concentrations when they are PBS and 0.1N NaCl solution is greater than 15%. In terms of signal-to-noise ratio, the signal-to-noise ratio is the highest when it is 0.5% NP40PBS. Because the cleaning solution formula is set to 0.5% NP40PBS, 0.1% NP40PBS can be used as an alternative solution.

[0185] Table 5

[0186]

[0187] Example 4 Application of p-Tau217 mass spectrometry detection kit

[0188] A sample of patients who were treated in Chongqing was selected, including 20 patients with Alzheimer's disease and 20 healthy subjects. The kit of the present invention was used for testing. The results are shown in Table 6 and Figure 2 shown; from Figure 2 It can be seen that the content of p-Tau 217 in the AD patient group (AD1-20) and the healthy population (control group, control1-20) is different.

[0189] Table 6 Actual sample test results

[0190]

[0191]

[0192] Comparative Example 1

[0193] The difference from Example 3 is that no 15 Np-Tau 217 protein. In this comparative example, the repeatability, spike recovery rate, and clinical application performance of the analytical method for reagent sample detection were evaluated.

[0194] (1) Linearity verification: Recombinant phosphorylated Tau protein with final concentrations of 0.1 pg / mL, 1 pg / mL, 5 pg / mL and 30 pg / mL was added to 1 mL of blank plasma to prepare a calibration curve, and the sample processing and detection were performed according to the sample processing process of Example 4. The ratio of the signal intensity of the peptide segment corresponding to the target protein to the signal intensity of the isotope peptide segment (peak area ratio) was used as the ordinate, and the concentration of the target protein was used as the abscissa to perform a linear fit. Figure 3 The calibration curve shown in the figure shows that the linear correlation coefficient R 2 =0.9674, indicating that without isotope peptide signal correction, the linearity of p-Tau 217 in the concentration range of 0.1-30pg / ml is poor.

[0195] (2) Repeatability test: Actual samples of different age groups (whose target proteins are known to differ) were tested separately, and the samples were processed three times in parallel according to the processing process of Comparative Example 1. The peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample. The results are shown in Table 7. It can be seen that the precision CV of the low-concentration sample measured in Comparative Example 1 is 19.14%, which is greater than 15%.

[0196] Table 7 Precision test results of comparative example 1

[0197] Group Sample 1 Sample 2 1 0.97 0.11 2 1.13 0.089 3 0.86 0.086 Mean 0.99 0.10 CV, % 13.76 19.14

[0198] (3) Accuracy determination: Recombinant phosphorylated Tau protein with a final concentration of 0.15 pg / mL and 0.8 pg / mL was added to the plasma, and the treatment and detection were carried out according to the operating steps of the kit of the present invention, and the peak area ratio was substituted into the calibration curve equation to calculate the concentration of the actual sample, according to accuracy = (test result after addition - background concentration) / theoretical concentration * 100%. The results are shown in Table 8, and it can be seen that the accuracy of comparative example 1 is <80%.

[0199] Table 8 Accuracy test results of Example 1

[0200] serial number Sample 1 Sample 2 Test results after spike 0.23 0.744 Background concentration 0.12 0.12 Accuracy, % 73.33 78.00

[0201] In summary, the present invention adds stable isotope-labeled p-Tau- 15N peptides can be used for accurate quantification of Tau-217 protein or its fragments. Since the isotope-labeled protein and the target protein have the same amino acid sequence, immune enrichment effect, distribution behavior, liquid chromatography retention time, mass spectrometry ionization efficiency and secondary fragmentation ions, due to the different mass numbers, the ratio of the peak intensities of the two can be obtained on the mass spectrum, and the amount of the corresponding hydrolyzed peptide in the sample can be further calculated by the amount of isotope-labeled peptides. Finally, the amount of the corresponding protein is obtained according to the stoichiometric value of the peptide. In particular, it is added during pretreatment, and the monitoring of the entire process (including sample dilution, immune enrichment, washing, digestion, desalting and other steps) can effectively overcome the losses caused by the need to extract p-Tau217 from the blood matrix, as well as the poor reproducibility inside and outside the laboratory and the large deviation from the actual content.

[0202] In addition, the detection method of p-Tau-217 protein or its fragment provided by the present invention has simple steps, short detection time, high sensitivity, good precision, high credibility of detection results, and only 5 steps are needed to complete the pre-treatment of mass spectrometry detection, and the required sample volume is reduced by about 75%, wherein the cleaning step is simplified, the acid precipitation, acid cleaning and solid phase extraction steps in the prior art are omitted, and the digestion and incubation time is greatly shortened. The present invention solves the problems of the existing Alzheimer's disease detection kit, such as complex operation, long time consumption, low sensitivity, poor precision, lack of accurate prediction ability of Alzheimer's disease, and has important application value and significance.

[0203] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A 15 Np-Tau protein, characterized in that Said 15 The preparation method of Np-Tau protein comprises the following steps: 1) Add GSK3β diluted with kinase dilution buffer I to a pre-cooled centrifuge tube, then add 15 N-Tau protein; 2) Add ATP diluted in kinase assay buffer, mix thoroughly and incubate; 3) Add GSK3β inhibitor, terminate the reaction, purify and obtain the 15 Np-Tau protein.

2. A method for detecting Tau protein or a fragment thereof, characterized in that: The detection method comprises adding the method as claimed in claim 1 during sample pretreatment 15 Steps of Np-Tau protein.

3. The detection method according to claim 2, characterized in that: The following steps are involved: 1) Sample pretreatment: Add sample diluent to the sample, then add the p-Tau- 15 N protein, to obtain solution A; 2) Immunoenrichment: Add the nanomagnetic microsphere-Tau 217 antibody complex to solution A for incubation, and pass through a magnetic rack to obtain a purified immune-enriched complex; 3) washing: washing the immuno-enriched complex with a non-ionic surfactant to obtain a washed complex; 4) adding NH4HCO3 to dissolve the washed complex, and then digesting and terminating; 5) Desalting, vacuum concentration and mass spectrometry injection; 6) Perform detection using mass spectrometry and output the results.

4. The detection method according to claim 3, characterized in that: The sample diluent in step 1) comprises: Tris-HCl, NaCl, EDTA, protease inhibitors and phosphatase inhibitors; and / or In step 1), the sample diluent further comprises NP40 and / or Tween 20.

5. The detection method according to claim 3, characterized in that: The sample diluent in step 1) comprises: 20-80 mM Tris-HCl, 30-80 mM NaCl, 1-10 mM EDTA, and 0.02%-0.2% by mass of protease inhibitors and 0.02%-0.2% by mass of phosphatase inhibitors; and / or The sample diluent in step 1) further comprises NP40 and / or Tween 20 at a mass fraction of 0.1%-1%; and / or Step 1) 15 Np-Tau protein was at a concentration of 0.5-5 pg / mL 15 Np-Tau 217 aqueous solution.

6. The detection method according to claim 3, characterized in that: Step 2) includes: adding the nanomagnetic microsphere-p-Tau217 antibody complex to solution A, incubating with rotation at room temperature for at least 2 hours, passing through a magnetic rack to obtain a purified immune-enriched complex.

7. The detection method according to claim 3, characterized in that: Step 3) comprises: washing the immuno-enriched complex at least three times with a PBS solution containing NP40 at a mass fraction of 0.1%-0.5%.

8. The detection method according to claim 3, characterized in that: Step 4) comprises: adding 20-200 mM NH4HCO3 to dissolve the washed complex, adding trypsin to digest for at least 8 hours, and adding formic acid aqueous solution to terminate the digestion.

9. A detection kit for p-Tau 217 protein or a fragment thereof, characterized in that: include: 1) Pretreatment module: at least including sample diluent and the 15 Np-Tau217 peptide segment, wherein the sample diluent comprises: NP40 with a mass fraction of 0.1%-1%, Tween 20 with a mass fraction of 0.1%-1%, Tris-HCl with a concentration of 20-80mM, NaCl with a concentration of 30-80mM, protease inhibitor with a mass fraction of 0.02%-0.2%, and phosphatase inhibitor with a mass fraction of 0.02%-0.2%; wherein p-Tau- 15 N-peptide fragment is 0.5-5pg / mL 15 Np-Tau 217 aqueous solution; 2) Immune enrichment module: including nanomagnetic microspheres-p-Tau 217 antibody complex; 3) Cleaning the digestion module: including a PBS solution with a mass fraction of 0.1%-0.5% NP40 and a NH4HCO3 solution with a concentration of 20-200mM; 4) Desalination module: including methanol, 80% by volume acetonitrile aqueous solution, and 1% by volume formic acid aqueous solution; 5) Drying and injection module: including a 1% by volume formic acid aqueous solution.

10. Use of the detection kit for p-Tau 217 protein or a fragment thereof according to claim 9 in the early diagnosis of Alzheimer's disease.

Citation Information

Patent Citations

  • Joint detection kit for detecting Alzheimer and application of joint detection kit

    CN114324890A

  • Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same

    US20090233373A1

  • Phosphospecific antibodies recognising tau

    US20140294731A1

  • Methods of treating based on site-specific TAU phosphorylation

    US20200400689A1

  • Anti-TAU MTBR antibodies and methods to detect cleaved fragments of TAU and uses thereof

    WO2024044637A2